Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Brain Imaging Study of the Effects of Modafinil in Cocaine Addiction (CAIMAN)

This study has been completed.
Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris Identifier:
First received: June 18, 2008
Last updated: April 10, 2013
Last verified: April 2013

-Context: Study objectives Primary: impact of modafinil versus placebo on DAT density modifications in the striatal and extra-striatal regions in cocaine dependent subjects hospitalised from D3 to D21.

Primary Hypothesis:

More rapid normalisation of DAT concentrations measured by PET using modafinil versus placebo from D3 to D21 during cocaine detoxification.

Condition Intervention Phase
Cocaine Addiction
Cocaine Dependence
Drug: Modafinil and PET (brain imaging)
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Dopamine Transporter (DAT) in Pharmacological Treatments of Cocaine Dependence. CAIMAN (Cocaine Addiction Imaging Medications and Neurotransmitters) Study

Resource links provided by NLM:

Further study details as provided by Assistance Publique - Hôpitaux de Paris:

Primary Outcome Measures:
  • Decreased DAT occupation rates in the modafinil group versus placebo from day 3 to day of cocaine detoxification. [ Time Frame: day 3 and day of cocaine detoxification ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluation of the clinical efficacy of modafinil during therapeutic cocaine withdrawal. [ Time Frame: D3 to D90 ] [ Designated as safety issue: No ]
  • Correlation between craving measurements, depressive symptom measurements and cognitive deficit measurements observed and modifications of DAT density. [ Time Frame: D3 to D21 ] [ Designated as safety issue: No ]
  • Study of DAT from D3 to D21 versus a pre-existing data base of control subjects. [ Time Frame: D3 to D21 ] [ Designated as safety issue: No ]
  • Tolerance and safety evaluation of high modafinil doses, measured by adverse events and biological parameters. [ Time Frame: D3 to D90 ] [ Designated as safety issue: Yes ]

Enrollment: 29
Study Start Date: April 2009
Study Completion Date: January 2013
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Drug: Modafinil and PET (brain imaging)
duration 90 days
Other Name: Modafinil and PET (brain imaging)
Placebo Comparator: 2
Drug: placebo
duration 90 days
Other Name: placebo

  Show Detailed Description


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men of at least 18 years of age
  • Cocaine dependent according to DSM IV TR criteria
  • Seeking treatment
  • Capable of understanding and giving their informed written consent
  • With National Health coverage
  • Urinary screen positive for cocaine in the weeks prior to inclusion

Exclusion Criteria:

  • Women
  • Other DSM IV TR axe I diagnostic criteria (except for tobacco)
  • Neurological disorders
  • Treatment that interferes with the DAT and modafinil
  • Contraindications for modafinil and Magnetic Resonance Imaging
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00701532

Unité de recherche U797 Inserm - CEA - Université Paris-Sud. " Neuroimagerie & Psychiatrie " Service Hospitalier Frédéric Joliot
Orsay, France, 91401
Centre d'Enseignement, de Recherche et de Traitements des Addictions - Hopital Universitaire Paul Brousse
Villejuif, France, 94800
Sponsors and Collaborators
Assistance Publique - Hôpitaux de Paris
Mission Interministérielle de Lutte contre la Drogue et la Toxicomanie
Study Director: Michel Reynaud, PhD Assistance Publique - Hôpitaux de Paris Hôpital Paul Brousse
  More Information

No publications provided

Responsible Party: Assistance Publique - Hôpitaux de Paris Identifier: NCT00701532     History of Changes
Other Study ID Numbers: P070150
Study First Received: June 18, 2008
Last Updated: April 10, 2013
Health Authority: France: Ministry of Health

Keywords provided by Assistance Publique - Hôpitaux de Paris:
Substance abuse
Brain imaging

Additional relevant MeSH terms:
Behavior, Addictive
Cocaine-Related Disorders
Chemically-Induced Disorders
Compulsive Behavior
Impulsive Behavior
Mental Disorders
Substance-Related Disorders
Anesthetics, Local
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses
Vasoconstrictor Agents
Wakefulness-Promoting Agents processed this record on November 25, 2014